ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
Provided By GlobeNewswire
Last update: Jul 31, 2025
Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients
Safety profile supports further clinical development, with no dose-limiting toxicities observed in patients with front-line NSCLC
Read more at globenewswire.com
